Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool December 6, 2005 Stephen D. Simpson	Tysabri Tries Again Will the FDA finally approve Elan's multiple sclerosis drug? Investors' fingers are crossed.
The Motley Fool February 28, 2005 Charly Travers	Another Drug Sector Shocker Patient death triggers voluntary withdrawal of MS drug Tysabri. Both BiogenIDEC and Elan have been rocked in trading today, down 41% and 68%, respectively, so far.
The Motley Fool January 25, 2010 Brian Orelli	No Way to Hide This Drug Approval FDA trumps Acorda on its good news. The biotech announced Food and Drug Administration approval of Ampyra, its drug to help multiple sclerosis patients walk better after the markets closed on Friday.
The Motley Fool April 5, 2005 Charly Travers	Has Elan Been KO'd? Tysabri is derailed but not necessarily off-track forever. The FDA needs to consider whether the real benefits to these patients outweigh the risk. But that's a highly uncertain outcome and a heck of decision on which to bet some investment dollars.
The Motley Fool April 21, 2011 Brian Orelli	Tysabri Means Everything to Biogen and Elan ... for Now It's rare to find a drug that affects two companies as much as Tysabri does Biogen Idec and Elan.
The Motley Fool January 16, 2008 Brian Lawler	More Tysabri on the Way Biogen and Elan receive an additional approval for Tysabri. Investors, take note.
The Motley Fool June 18, 2007 Billy Fisher	Elan Elevates Its Game New drug prospects push the Dublin-based biotech's shares to a new 52-week high.
The Motley Fool June 8, 2010 Brian Orelli	Injecting Uncertainty Into the Multiple Sclerosis Market Novartis' oral MS drug could be a blockbuster -- if it can get past the FDA.
The Motley Fool August 26, 2008 Brian Lawler	FDA Changes Course for Elan and Biogen Idec The agency takes a different tack with one of the partnership's top drugs.
The Motley Fool February 16, 2010 Brian Orelli	For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward.
The Motley Fool March 31, 2005 Stephen D. Simpson	Strike Three for Tysabri A third confirmed case of PML all but eliminates Tysabri's potential as a blockbuster drug. For Elan and Biogen investors, the news continues to sting.
The Motley Fool December 7, 2004 Charly Travers	Spin the Medicine Bottle Is a new MS drug going to be a top seller or a bottom-dweller? Here's how to find out. Before investing in any pharmaceutical company with a product in development, go through this exercise to estimate the new drug's potential.
The Motley Fool June 29, 2004 Charly Travers	Antegren Gets Priority Review The FDA steps up the drug's time line for approval.
The Motley Fool May 26, 2010 Brian Orelli	Blockbuster Drugs Aimed at Busting MS Multiple sclerosis is a large market with more entrants coming.
The Motley Fool February 25, 2010 Brian Orelli	Transplanting Future Revenue Bristol-Myers Squibb waits for experts to decide the fate of its kidney cancer drug.
The Motley Fool July 21, 2010 Brian Orelli	Biogen Looks Good Now, but What About Tomorrow? Biogen Idec saw revenue increase 11% and adjusted earnings per share jump almost 75%, which is all well and good, but the longer-term prospects for the company aren't nearly as impressive.
The Motley Fool March 26, 2009 Brian Orelli	R&D Your Way to Higher Sales Biogen is trying to lower side effects to increase sales.
The Motley Fool August 10, 2005 Jack Uldrich	Does NanoCrystal Ball See All? There is promise in biotech Elan, but not for the reason you might think. Investors, take note.
The Motley Fool July 23, 2007 Brian Lawler	A Setback for Elan and Biogen Elan and Biogen receive negative news about Tysabri. The EU medical authorities won't allow its use as a treatment for Crohn's disease.
The Motley Fool March 17, 2005 Brian Gorman	Fear Catches Up to Glaxo Glaxo's MS research is in limbo as the FDA works to calm anxieties over Tysabri. Until the fear subsides, investors are likely to suffer.
The Motley Fool April 12, 2011 Brian Orelli	How Significant Is 'Statistically Significant' for Biogen? Biogen could have a third multiple sclerosis blockbuster on its hands.
Pharmaceutical Executive April 1, 2011	Off-Label But On Point? Use of off-label drugs is a balancing act for physicians, and poses even more problems for pharma. The FDA is moving slowly to help.
The Motley Fool December 31, 2010 Brian Orelli	2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions.
The Motley Fool April 7, 2011 Brian Orelli	Drug Approved! But Where's the Name? AstraZeneca prepares to cash in on a minuscule market.
The Motley Fool February 28, 2008 Brian Lawler	A Tysabri Heart Attack Biogen and Elan announce new warnings for multiple sclerosis drug Tysabri.
The Motley Fool April 29, 2011 Brian Orelli	Oral Multiple Sclerosis Drugs Heat Up Watch out Novartis and Gilenya.
The Motley Fool December 31, 2007 Brian Lawler	The Anatomy Of An Approved Drug An independent audit by the FDA provides a useful summary of the characteristics of drugs approved by the agency.
The Motley Fool January 21, 2011 Brian Orelli	Trouble in Tysabri Land? Patient additions for a drug from Biogen Idec and Elan are slowing down.
The Motley Fool September 22, 2010 Jordan DiPietro	A Huge Victory for Novartis MS oral drug is approved.
The Motley Fool October 27, 2010 Brian Orelli	Biogen Idec's Fight-Back Plan Novartis' Gilenya is coming, but Biogen has a backup plan.
The Motley Fool July 30, 2010 Brian Orelli	A Faster Pathway to Drug Approvals A thinktank called the Pacific Research Institute has proposed letting drugs approved by the European Medicines Authority onto the market in the U.S. before the Food and Drug Administration has approved the drugs.
The Motley Fool September 9, 2010 Brian Orelli	Will These Drugs Get Past the FDA This Month? See what the FDA has on its decision calendar for the rest of September.
The Motley Fool February 28, 2011 Brian Orelli	Rare Diseases, Big Opportunity "Orphan" drugs to keep your eye on.
BusinessWeek March 21, 2005 Catherine Arnst	On The Hot Seat At Biogen How Biogen CEO Jim Mullen managed a drug crisis after alarming news broke that the multiple sclerosis drug Tysabri may cause a deadly brain infection.
The Motley Fool June 29, 2010 Brian Orelli	The Final Obstacle to Your Drug Company Multibagger The dreaded FDA advisory committee meeting.
The Motley Fool January 12, 2010 Brian Orelli	Tysabri: It's a Blockbuster! Yawn. So What? Is it really a big deal that Tysabri finally achieved blockbuster status?
The Motley Fool November 1, 2010 Brian Orelli	Stock Doubles! No Crying Here AVANIR Pharmaceuticals' investors didn't have any uncontrolled crying on Friday when the Food and Drug Administration approved Nuedexta, the company's treatment for pseudobulbar affect.
The Motley Fool March 3, 2011 Brian Orelli	3 Cheers for an FDA Rejection German drugmaker Merck said that the Food and Drug Administration had turned down its multiple sclerosis drug cladribine. The pill would have competed with Novartis' Gilenya, which gained FDA approval last year.
The Motley Fool May 26, 2005 Stephen D. Simpson	Elan Holds Its Ground Elan clearly isn't throwing in the towel on Tysabri, but its fate is not solely in the company's hands. If you're pinning your hopes on a full return on this drug, you might be signing on for more risk than you really want.
The Motley Fool October 15, 2009 Robert Steyer	Little Discord on Acorda Drug FDA advisory panel overwhelmingly backs a drug to improve the walking ability of multiple sclerosis patients.
The Motley Fool April 14, 2011 Brian Orelli	Human Genome Sciences Will Be Profitable, Eventually With its first drug on the market -- nearly 20 years after the company was founded -- Human Genome Sciences should start to show meaningful revenue this year.
The Motley Fool March 28, 2011 Brian Orelli	Investors Jump for Yervoy! The Food and Drug Administration approval of Bristol-Myers Squibb's Yervoy came with some surprising labeling news.
The Motley Fool April 24, 2009 Brian Orelli	Great Drugs Not Living Up to Their Potential How well a drug works is not the most important thing to consider when investing. Drugs that work don't always become blockbusters.
The Motley Fool April 1, 2004 Charly Travers	Atrix Batting 1.000 Atrix Laboratories' drugs have breezed past the Food and Drug Administration.
The Motley Fool July 26, 2006 Brian Lawler	Biogen Slows Down Several potential growth drivers should help the biopharma. Ever since the merger with Idec, the company has been fairly well run (absent the Tysabri delays). Investors, take note.
The Motley Fool February 23, 2010 Brian Orelli	The One That Didn't Get Away After some encouragement, the FDA approves Gilead's Cayston.
The Motley Fool July 17, 2009 Brian Orelli	Tysabri Is Back! News about Biogen Idec and Elan's multiple sclerosis drug revenues, as well as those of Pfizer and Teva.
The Motley Fool March 8, 2010 Brian Orelli	Really? A 59% Share Price Jump for That? Justified or not, InterMune skyrockets ahead of an FDA panel meeting.
The Motley Fool November 29, 2010 Brian Orelli	There's Still Only One Merck KGaA's oral MS drug delay is Novartis' gain.
The Motley Fool April 26, 2011 Luke Timmerman	FDA Says Vertex Drug a Wee Bit More Effective Than Advertised; Stock Climbs Good news for Vertex?